China News Service, June 15 (Reporter Chen Jing) The reporter learned on the 15th that the innovative pharmaceutical company CStone Pharmaceuticals and Pfizer Biopharmaceutical Group have jointly developed a new drug for ROS1-positive lung cancer patients-lorlatinib .

The two parties will launch a clinical study on the ROS1 target in China, which is a key study of loratinib in this target.

  It is reported that in September last year, CStone Pharmaceuticals and Pfizer announced a strategic cooperation, including Pfizer’s US$200 million equity investment in CStone Pharmaceuticals, and CStone’s authorization to Pfizer for the development and commercialization of sugarizumab in mainland China. And the cooperation framework between CStone Pharmaceuticals and Pfizer to introduce more oncology products into the Greater China region.

  Dr. Jiang Ningjun, Chairman and CEO of CStone Pharmaceuticals, told reporters that day: “We look forward to working with Pfizer to bring more innovative tumor treatment products to patients with high quality and efficiency.”

  Pierre Gaudreault, President of Pfizer Biopharmaceutical Group China, said: “Globally, Pfizer has a variety of precision treatment drugs for gene mutations in the field of lung cancer. CStone Pharmaceuticals focuses on innovative tumor immunotherapy and precision treatment drugs. This cooperation injects strong clinical development capabilities. We look forward to both parties to further accelerate the safety and effectiveness of loratinib in Chinese patients with ROS1-positive advanced NSCLC, and help loratinib to benefit Chinese patients as soon as possible."

  CStone Pharmaceuticals has accumulated rich experience in the field of lung cancer research.

The company recently released the latest clinical trial results for its tumor immunotherapy product Shuglizumab, showing that the drug is significantly effective for patients with stage III non-small cell lung cancer (NSCLC), and Shuglizumab has become the world's first PD-1 or PD-L1 monoclonal antibody covering the entire population of stage III and stage IV non-small cell lung cancer at the same time.

  At present, CStone Pharmaceuticals has successfully marketed two precision treatment drugs in China, namely avatinib (trade name: Taijihua), a precision treatment drug for GIST with PDGFRA exon 18 mutation (including D842V mutation), and Pratinib, a highly selective RET inhibitor (trade name: Pugeta), is used for the treatment of RET fusion-positive adult patients with locally advanced or metastatic non-small cell lung cancer who have previously received platinum-containing chemotherapy.